Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Other Non-Current Assets (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Other Non-Current Assets for 10 consecutive years, with $1.2 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets changed N/A year-over-year to $1.2 million; the TTM value through Mar 2026 reached $1.2 million, changed N/A, while the annual FY2025 figure was $107000.0, N/A changed from the prior year.
  • Other Non-Current Assets hit $1.2 million in Q1 2026 for Crescent Biopharma, up from $107000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.2 million in Q1 2022 and bottomed at $50000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $426938.9, with a median of $107000.0 recorded in 2025.
  • Year-over-year, Other Non-Current Assets skyrocketed 4145.81% in 2022 and then plummeted 97.64% in 2023.
  • Crescent Biopharma's Other Non-Current Assets stood at $50000.0 in 2022, then skyrocketed by 208.35% to $154176.0 in 2023, then tumbled by 66.06% to $52320.0 in 2024, then skyrocketed by 104.51% to $107000.0 in 2025, then soared by 983.18% to $1.2 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.2 million, $107000.0, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.